Correlation of HER2 levels expression through HER2 mRNA PCR vs immunohistochemistry (IHC) in hormone receptor positive (HR+)/HER2 negative (HER2−) early breast cancer
We found that HER2 mRNA measurement by Oncotype DX provides a quantitative approach to assess HER2 expression. However, its results overlap within traditional IHC categories. While HER2-low classification may have therapeutic implications for new antibody-drug conjugates, its prognostic relevance appears limited. Further studies are needed to improve HER2 quantification methods for improved clinical decision-making.
Authors
- Cristina Díaz del Arco (ORCID: https://orcid.org/0000-0002-6100-4967)
- Alfonso López de Sá
- Beatriz González
- José Á. García-Sáenz (ORCID: https://orcid.org/0000-0001-6880-0301)
- Alicia De Luna
- Fernando Moreno (ORCID: https://orcid.org/0000-0001-8933-0687)
- Julia Tejerina
- Mateo Paz-Cabezas (ORCID: https://orcid.org/0000-0003-4144-8381)
- Michael Amann (ORCID: https://orcid.org/0000-0001-8041-4083)
- Vanesa García‐Barberán (ORCID: https://orcid.org/0000-0002-2531-0203)
- Pablo Ballestín
- Alejandro Pascual
Institutions
- Hospital Clínico San Carlos (ES)
- Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (ES)
Publication Details
- Journal
- Clinical & Translational Oncology
- Published
- 2025-08-20
- DOI
- https://doi.org/10.1007/s12094-025-03999-7
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Universidad Complutense de Madrid